Annals of Pulmonary and Critical Care Medicine (APCCM) a peer-reviewed online publishing journal.
The company has been focused on advancing OT-101 as an immunotherapy for the treatment of cancer and the program is ready for advancement into phase 3 studies based on data from over 200 patients that support its activity and safety.
Upon assessing the broad impact of the SARS-CoV-2 virus and associated COVID-19 complications the company tested its lead compound that showed potent activity in the lab and promising data for treating the virus infection and associated complications based on the OT-101 mechanism of action.
Mateon has two candidates, OT-101 (Trabedersen) and Artemisinin, that can immediately be advanced in COVID-19 clinical trials.
FDA has been engaged for OT-101 for a COVID-19 patient study
